NVAX Stock — Novavax Inc

Up next

Next earnings call

Nov 6, 2026 Est · unconfirmed · in 9 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

AI Brief

Q1 FY26 earnings call · May 6, 2026

Q1 FY26

TL;DR. Novavax reported Q1 2026 total revenue of $140 million, highlighted its expanding Matrix-M partnering strategy with Pfizer and four additional MTAs, and prioritized its C. difficile vaccine candidate for potential clinic entry as early as 2027, while reiterating its 2026 revenue framework and combined R&D and SG&A guidance.

Bullish

+ Total revenue of $140 million in Q1 2026 and reiterated 2026 revenue framework and combined R&D and SG&A guidance. new
+ Pfizer license agreement in January 2026 included a $30 million upfront payment, with up to $500 million in additional development and sales milestones plus high-mid-single digit percentage royalties.
+ Sanofi partnership has delivered over $800 million in revenue to date. new
+ Sanofi announced positive Phase 4 COMPARE study results comparing Nuvaxovid head-to-head with Moderna's mNEXSPIKE. new
+ Expanded Matrix-M reach with four new MTAs in 2026, including a top 10 pharma/oncology leader, bringing partnerships to four of the top 10 global pharma companies exploring over 30 unique fields. new
+ C. difficile vaccine candidate prioritized, with potential to enter the clinic as early as 2027, addressing an estimated $1.5–$2 billion commercial opportunity. new

Bearish

− C. difficile vaccine candidate is still pre-IND, with IND-enabling repeat dose toxicity study ongoing and no FDA pre-IND dialogue yet. new
− Sanofi's combination COVID/flu programs are awaiting agency alignment and next steps, with timing of updates uncertain. new
− C. difficile commercial estimate of $1.5–$2 billion already assumes the presence of other competitors including Pfizer in the market. new
− Novavax does not plan to advance its RSV and VZV preclinical assets into human trials, reflecting a narrower internal pipeline focus. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.70

Technical

price trend

Buy

50 / 200-day cross Death cross

Price vs 200-day avg +10%

above

Price vs 50-day avg +11%

above

RSI (14) 64

neutral

MACD trend Positive

52-week position 63%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return +26%

trailing

6-month return −12%

trailing

YTD return +39%

this year

Relative strength −26%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) Death cross

50d $8 › 200d $8 — 200d above 50d

Institutional flow Accumulating

+3% holders QoQ · +42 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

28.79% of float · ▲ +4.0% MoM · 14.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

270 holders — near 3-yr high, broad support

Squeeze score 80

high risk · 0–100

Fundamentals

Excellent

Revenue growth +65%

Y/Y

EPS growth +310%

Y/Y

Balance sheet $3.6M

net debt

Quant / Vol

risk profile

Very High

Volatility 64%

annualized · 1-yr

Max drawdown −35%

past year

ATR 5.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 1 of last 4

Latest guidance · from the 8-K filed May 6, 2026

Combined R&D and SG&A Expenses · Full Year 2026 Initiated $380M – $420M

Non-GAAP Combined R&D and SG&A Expenses · Full Year 2026 Non-GAAP Initiated $310M – $340M

Adjusted Total Revenue · Full Year 2026 Non-GAAP Initiated $230M – $270M

Adjusted Supply Sales · Full Year 2026 Initiated $40M – $50M

Nuvaxovid Product Sales · Full Year 2026 Initiated $35M – $45M

Adjusted Licensing, Royalties and Other Revenue · Full Year 2026 Non-GAAP Initiated $155M – $175M

Prior guidance period ended · from the 8-K filed Jan 12, 2026

Combined R&D and SG&A Expenses, Net of Partner Reimbursement · FY 2025 E $250M

Guided vs delivered · last 4 settled

Total Revenue Full Year 2024

guided $650M – $700M

guided $650M – $700M $682.16M In line

Total revenue first quarter 2024

guided $100M

guided $100M $93.86M Miss −6.1%

Total revenues 2023

guided $1B

guided $1B $983.71M Miss −1.6%

Total revenue this year

guided $4B – $5B

guided $4B – $5B $1.98B Miss −56.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

Death cross Bearish

Price vs 200-day avg

+10% Bullish

Price vs 50-day avg

+11% Bullish

RSI (14)

64 Neutral

MACD trend

Positive Bullish

52-week position

63% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) Death cross

50d $8 › 200d $8 — 200d above 50d

Institutional flow Accumulating

+3% holders QoQ · +42 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

28.79% of float · ▲ +4.0% MoM · 14.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

270 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $6 Now $9 · 63% Range high $11

vs 200-day avg +10% vs 50-day avg +11% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Non-GAAP R&D Expenses, net of partner reimbursement non-GAAP	$48M	Q2 2026	—

Sanofi milestones achieved	$225M	2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NVAX Novavax Inc this stock	$1.53B	+39.4%	+64.7%	—	28.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$137.30B	+20.1%	+46.2%	31.6	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$81.77B	+3.5%	+20.8%	19.7	2.3%
ARGX Argenx SE	$64.16B	+22.7%	—	—	1.9%
CSLLY Csl Ltd	$59.23B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

270

% held: 77.7%
Net QoQ: +993.7K sh
Top holder: SHAH CAPITAL MANAGEMENT

Held Float

View

Held by Funds

Fund positions

171

View

Short & Settlement

Short Interest Rising

Shares short

47.5M

Days to cover: 14.0d
Change: +1.8M sh

View

Short Volume

Short vol %

37%

As of: Aug 31, 2026

Short Total

View

Fails to Deliver

FTD shares

2.1K

Value: $16.9K
As of: Aug 13, 2026

View

Off-Exchange

Off-exchange %

40.4%

Week of: Jul 27, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Pat Roberts

Amount: $1.0K–$15.0K
Traded: Oct 13, 2020

View

Financials

Revenue (FY)

$1.1B

Net income (FY): $440.3M
EPS diluted: $2.58

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 11

View

Proposed Sales

Value

$75.9K

Shares: 10.0K
Filed: May 19, 2025

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

	5D	20D	120D	MTD	YTD
NVAX	+5.8%	+26.5%	-12.4%	+28.0%	+39.4%
SPY	+0.5%	+1.2%	+13.3%	+2.7%	+12.5%
vs SPY	+5.3%	+25.2%	-25.6%	+25.3%	+27.0%

NVAX · Novavax Inc

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance